Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 22:13:2024-3-5.
doi: 10.7573/dic.2024-3-5. eCollection 2024.

Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review

Sara Munari #  1   2 , Giulia Ciotti #  3 , Walter Cestaro #  1   2 , Lorenzo Corsi #  2   4 , Silvia Tonin #  2   4 , Andrea Ballarin #  4 , Ariel Floriani #  4 , Cristina Dartora #  4 , Annamaria Bosi #  4 , Matteo Tacconi #  4 , Francesco Gialdini #  1 , Michele Gottardi #  3 , Francesco Menzella #  2   4
Affiliations
Review

Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review

Sara Munari et al. Drugs Context. .

Abstract

Type 2 inflammation is a heterogeneous condition due to the complex activation of different immunological pathways. Rapid progress in research to evaluate the efficacy of biologics for chronic rhinosinusitis with nasal polyps and asthma has led to the availability of effective therapeutic options. These drugs are safe, but temporary iatrogenic hypereosinophilia may sometimes be associated with clinical symptoms or organ damage. Here, we describe a case of severe hypereosinophilia in a patient with chronic rhinosinusitis with nasal polyps and asthma treated with dupilumab and a subsequent therapeutic shift to mepolizumab that led to maintenance of symptom control and concomitant normalization of blood eosinophil count.

Keywords: asthma; chronic rhinosinusitis with nasal polyps; clonal haematopoiesis; dupilumab; hypereosinophilia; mepolizumab.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2024/05/dic.2024-3-5-COI.pdf

Similar articles

See all similar articles

Cited by

References

    1. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425–437. doi: 10.1080/1744666X.2017.1298443. - DOI - PubMed
    1. Chen S, Zhou A, Emmanuel B, et al. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36:1897–1911. doi: 10.1080/03007995.2020.1815682. - DOI - PubMed
    1. Wautlet A, Bachert C, Desrosiers M, et al. The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics. J Allergy Clin Immunol Pract. 2023;11(9):2642–2651. doi: 10.1016/j.jaip.2023.04.054. - DOI - PubMed
    1. Muñoz del Castillo F, Jurado-Ramos A, Fernández-Conde BL, et al. Allergenic profile of nasal polyposis. J Investig Allergol Clin Immunol. 2009;19(2):110–116. - PubMed
    1. Fokkens JF, Lund VJ, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319. doi: 10.1111/all.13875. - DOI - PMC - PubMed